Unravel Biosciences

Executive Summary

Unravel Biosciences is a preclinical-stage biotechnology company based in Cambridge, MA, that combines artificial intelligence and systems biology to accelerate drug discovery and repurposing. Founded in 2019, the company leverages patient-derived RNA data to construct 'Living Molecular Twins'—computational models of biological networks—to identify and clinically derisk new therapeutic targets for complex disorders. Its initial focus is on rare neurological diseases, particularly Rett syndrome, for which it aims to rapidly advance existing drugs into clinical trials. By integrating multi-omics data with network medicine, Unravel seeks to shorten development timelines and reduce the high failure rates typical of traditional drug discovery. The company operates in a capital-efficient manner, utilizing repurposed compounds that already have safety data, potentially enabling faster and less costly paths to approval. While still early in its development, Unravel's platform-driven approach addresses a critical need for effective treatments in rare diseases and has attracted interest from the biotech community.

Upcoming Catalysts (preview)

• Q4 2026Lead program (Rett syndrome) enters clinical trials30% success
• Q3 2026Series A funding round closure60% success
• TBDPartnership with a larger pharma or rare disease foundation40% success